• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TCR2 Therapeutics Inc. - Common Stock (NQ:TCRR)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, May 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about TCR2 Therapeutics Inc. - Common Stock

News headline image
TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 11, 2023
From TCR2 Therapeutics
Via GlobeNewswire
News headline image
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 08, 2023
From TCR2 Therapeutics
Via GlobeNewswire
News headline image
TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRR
April 26, 2023
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2023
From TCR2 Therapeutics
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Diffusion Pharmaceuticals Inc. (Nasdaq- DFFN), U.S. Xpress Enterprises, Inc. (NYSE – USX), TCR² Therapeutics Inc. (Nasdaq – TCRR), Costar Technologies, Inc. (OTC –
March 30, 2023
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
March 23, 2023
From TCR2 Therapeutics
Via GlobeNewswire
News headline image
TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRR
March 08, 2023
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
TCR2 Therapeutics (NASDAQ: TCRR) and Adaptimmune Therapeutics (NASDAQ: ADAP) Announce Strategic Merger to Leverage Technologies and Create a New Major Cell Therapy Company
March 06, 2023
TCR2 Therapeutics, Inc. (NASDAQ: TCRR) operates as a clinical-stage immunotherapy company, which is focused on the research and development of 
Via Spotlight Growth
News headline image
TCRR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of TCR² Therapeutics Inc. Is Fair to Shareholders
March 06, 2023
From Halper Sadeh LLC
Via Business Wire
News headline image
Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
March 06, 2023
Compelling clinical data with clear paths to products and multiple near‐term value-creating catalystsComplementary technology platforms designed to treat solid tumors... 
Via Newsfile
News headline image
Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
March 06, 2023
From TCR2 Therapeutics
Via GlobeNewswire
News headline image
TCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023
February 08, 2023
From TCR2 Therapeutics
Via GlobeNewswire
News headline image
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 05, 2023
From TCR2 Therapeutics
Via GlobeNewswire
News headline image
TCR² Therapeutics Announces Pipeline Priorities for 2023
January 05, 2023
From TCR2 Therapeutics
Via GlobeNewswire
News headline image
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 01, 2022
From TCR2 Therapeutics
Via GlobeNewswire
News headline image
TCR² Therapeutics to Present at the Piper Sandler Healthcare Conference
November 23, 2022
From TCR2 Therapeutics
Via GlobeNewswire
News headline image
TCR² Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 08, 2022
From TCR2 Therapeutics
Via GlobeNewswire
News headline image
TCR² Therapeutics Presents Preclinical Data on Functional Activity of Gavo-cel at the Society for Immunotherapy of Cancer
November 07, 2022
From TCR2 Therapeutics
Via GlobeNewswire
News headline image
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 01, 2022
From TCR2 Therapeutics
Via GlobeNewswire
News headline image
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2022
From TCR2 Therapeutics
Via GlobeNewswire
News headline image
gavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Reponses in Ovarian Cancer and Mesothelioma
September 28, 2022
From TCR2 Therapeutics
Via GlobeNewswire
News headline image
TCR² Therapeutics to Announce Complete Phase 1 Portion of the Gavo-cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid Tumors
September 27, 2022
From TCR2 Therapeutics
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap